Schwersenz I - Search Results

1

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.

Pechmann A, Behrens M, Dörnbrack K, Tassoni A, Stein S, Vogt S, Zöller D, Bernert G, Hagenacker T, Schara-Schmidt U, Schwersenz I, Walter MC, Baumann M, Baumgartner M, Deschauer M, Eisenkölbl A, Flotats-Bastardas M, Hahn A, Horber V, Husain RA, Illsinger S, Johannsen J, Köhler C, Kölbel H, Müller M, von Moers A, Schlachter K, Schreiber G, Schwartz O, Smitka M, Steiner E, Stögmann E, Trollmann R, Vill K, Weiß C, Wiegand G, Ziegler A, Lochmüller H, Kirschner J; SMArtCARE study group. Pechmann A, et al. Among authors: schwersenz i. Brain. 2023 Feb 13;146(2):668-677. doi: 10.1093/brain/awac252. Brain. 2023. PMID: 35857854

2

Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.

Schorling DC, Kölbel H, Hentschel A, Pechmann A, Meyer N, Wirth B, Rombo R; SMArtCARE consortium; Sickmann A, Kirschner J, Schara-Schmidt U, Lochmüller H, Roos A. Schorling DC, et al. Eur J Neurol. 2022 Jul;29(7):2084-2096. doi: 10.1111/ene.15331. Epub 2022 May 4. Eur J Neurol. 2022. PMID: 35318785

3

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.

Pechmann A, König K, Bernert G, Schachtrup K, Schara U, Schorling D, Schwersenz I, Stein S, Tassoni A, Vogt S, Walter MC, Lochmüller H, Kirschner J. Pechmann A, et al. Among authors: schwersenz i. Orphanet J Rare Dis. 2019 Jan 21;14(1):18. doi: 10.1186/s13023-019-0998-4. Orphanet J Rare Dis. 2019. PMID: 30665421 Free PMC article.

4

[Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience].

Walter MC, Dräger B, Günther R, Hermann A, Hagenacker T, Kleinschnitz C, Löscher W, Meyer T, Schrank B, Schwersenz I, Wurster CD, Ludolph AC, Kirschner J. Walter MC, et al. Among authors: schwersenz i. Nervenarzt. 2019 Apr;90(4):343-351. doi: 10.1007/s00115-018-0653-7. Nervenarzt. 2019. PMID: 30617569 Review. German.

5

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients.

Lochmüller H, Evans D, Farwell W, Finkel R, Goemans N, de Lemus M, Matyushenko V, Muntoni F, Ouillade MC, Schwersenz I, Wilson P. Lochmüller H, et al. Among authors: schwersenz i. J Neuromuscul Dis. 2018;5(2):131-133. doi: 10.3233/JND-180325. J Neuromuscul Dis. 2018. PMID: 29865093 Free PMC article. No abstract available.

6

Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients.

Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, Schwersenz I, Bellis G, Cottet C. Rouault F, et al. Among authors: schwersenz i. Neuromuscul Disord. 2017 May;27(5):428-438. doi: 10.1016/j.nmd.2017.01.018. Epub 2017 Feb 3. Neuromuscul Disord. 2017. PMID: 28237437

7

SMA-EUROPE workshop report: Opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe.

Kayadjanian N, Burghes A, Finkel RS, Mercuri E, Rouault F, Schwersenz I, Talbot K. Kayadjanian N, et al. Among authors: schwersenz i. Orphanet J Rare Dis. 2013 Mar 20;8:44. doi: 10.1186/1750-1172-8-44. Orphanet J Rare Dis. 2013. PMID: 23514578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters